Zevra Therapeutics, Inc. (ZVRA) Misses Q3 EPS by 28c

Zevra Therapeutics, Inc. (NASDAQ: ZVRA) reported Q3 EPS of ($0.69), $0.28 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $3.69 million versus the consensus estimate of $4.87 million.

For earnings history and earnings-related data on Zevra Therapeutics, Inc. (ZVRA) click here.

You May Also Be Interested In

• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• Draganfly wins Canadian Armed Forces drone contract for up to 5,000 units
• Fuel Tech wins $2.8M in air pollution control contracts